| Atrial Fibrillation Management and Outcomes | Lifetime | 64 | US 29 | 99.80 |
| Pharmaceutical Economics and Policy | Lifetime | 16 | US 12 | 99.35 |
| Lipoproteins and Cardiovascular Health | Lifetime | 59 | US 35 | 99.65 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 59 | US 26 | 99.63 |
| Acute Myocardial Infarction Research | Lifetime | 90 | US 55 | 99.71 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 147 | US 59 | 99.52 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 181 | US 89 | 99.39 |
| Cardiac Arrhythmias and Treatments | Lifetime | 167 | US 91 | 99.47 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 405 | US 219 | 98.90 |
| Cardiac Imaging and Diagnostics | Lifetime | 711 | US 362 | 98.90 |
| Coronary Interventions and Diagnostics | Lifetime | 362 | US 165 | 98.92 |
| Cancer, Lipids, and Metabolism | Lifetime | 404 | US 208 | 98.41 |
| Heart Failure Treatment and Management | Lifetime | 586 | US 278 | 97.89 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 777 | US 314 | 97.52 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 161 | US 59 | 96.45 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 736 | US 269 | 95.74 |
| GDF15 and Related Biomarkers | Lifetime | 254 | US 90 | 88.72 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 58 | US 16 | 99.35 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 39 | US 19 | 99.18 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 62 | US 23 | 98.15 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 92 | US 31 | 97.13 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 122 | US 26 | 97.01 |
| Cardiac Arrhythmias and Treatments | 2021-2025 | 286 | US 77 | 97.55 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 537 | US 179 | 95.40 |
| Venous Thromboembolism Diagnosis and Management | 2021-2025 | 605 | US 197 | 94.00 |
| Cardiac electrophysiology and arrhythmias | 2021-2025 | 572 | US 151 | 92.99 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 293 | US 60 | 88.38 |
| Pharmaceutical Economics and Policy | 2021-2025 | 354 | US 129 | 84.61 |
| GDF15 and Related Biomarkers | 2021-2025 | 157 | US 47 | 76.74 |
| Lipid metabolism and disorders | 2021-2025 | 656 | US 132 | 66.82 |
